What is the Grant for Oncology Innovation?

The Grant for Oncology Innovation (GOI) will not be accepting proposals for the award in its current format for 2018. EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany is committed to innovation and rewarding new thinking that could address the enormous unmet need in cancer care. To best address this, we are transforming the GOI to a more patient-centric focus. By connecting and empowering the oncology community, enabling and accelerating innovative drug discovery, and driving the clinical understanding of rare tumors with high unmet need, we will reach our shared goal – the delivery of innovative treatment to people with cancer. EMD Serono, Inc.,a business of Merck KGaA, Darmstadt, Germany will announce details of the new program in the coming months. Please check this website for updates.

Investigators leading innovative research projects that have the potential to advance the implementation of personalized treatment for solid tumors are invited to apply.
Potential research topics that could be funded through the Grant for Oncology Innovation include: Research on molecular biomarkers or new targeted treatments; technology platforms for the routine analysis of molecular biomarkers; and side-effect management and platforms or tools that allow patients to access individualized treatment.

Any potential research project may involve products from Merck or competitors, if used
on-label and if the aim(s) of the research is/are not to evaluate or compare the efficacy and/or safety of the product(s). The research project may involve prospective sampling if the sampling is part of non-interventional studies* and not part of interventional
clinical trials.**
 
Non-interventional study – definition:
*A non-interventional study is defined as a study where the medicinal product(s) is (are) prescribed in the usual manner in accordance with the terms of the marketing authorization. The assignment of the patient to a particular therapeutic strategy is not decided in advance by a trial protocol but falls within current practice, and the prescription of the medicine is clearly separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures shall be applied to the patients. Epidemiologic methods shall be used for the analysis of collected data and not part of interventional clinical trials.**
 
Interventional clinical trial – definition:
**An interventional clinical trial is defined as a clinical study in which participants are assigned to receive one or more interventions so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. The assignments are determined by the study protocol. Participants may receive diagnostic, therapeutic, or other types of interventions.

A total, annual grant of up to €1,000,000 will be shared by a number of selected projects.
Research proposals with budgets of up to €500,000 will be considered.

The grant is built on the success of the Grant for Fertility Innovation (GFI) and the Grant for Multiple Sclerosis Innovation (GMSI), which, between them, have awarded grants totaling over €10,000,000 to translational research projects since 2010.

Applications will be evaluated by an external, fully independent Scientific Steering Committee consisting of internationally renowned clinical oncologists and researchers.